Data as of Jun 18
| +0.65 / +4.72%|
The 5 analysts offering 12-month price forecasts for Momenta Pharmaceuticals Inc have a median target of 17.00, with a high estimate of 18.00 and a low estimate of 13.00. The median estimate represents a +17.97% increase from the last price of 14.41.
The current consensus among 7 polled investment analysts is to Hold stock in Momenta Pharmaceuticals Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.